文献速递头颈部肿瘤放疗

绿袍散治疗头颈部癌放疗所致黏膜炎疗效:114例患者回顾性研究

Efficacy of Lvpao Powder on Radiation Therapy-Induced Mucositis: A Retrospective Study of 114 Patients With Head and Neck Carcinoma.
PubMed 文献 · Adv Radiat Oncol · 2023-12-30

该回顾性研究分析本中心114例头颈部恶性肿瘤患者,比较康复新液单用与康复新液联合绿袍散喷雾对放疗所致口腔黏膜炎的疗效与安全性。联合组3级黏膜炎发生率、疼痛评分、症状缓解时间和体重下降均低于单药组,张口受限无统计学差异。作者认为绿袍散作为黏膜修复药物安全有效,可加速恢复并减少体重下降。

要点

  • 联合组3级黏膜炎11.4%(5/44)低于康复新液组32.9%(23/70),P=0.009。
  • 联合组疼痛评分3.75±1.03低于单药组4.26±0.81,P=0.007。
  • 联合组症状缓解时间3天短于单药组6天,体重下降5.95±0.94 kg少于6.67±1.20 kg。

核心结论

  • 作者认为绿袍散作为黏膜修复药物安全有效,可加速患者恢复并减少体重下降。

研究设计与样本

  • 回顾性分析本中心114例头颈部恶性肿瘤患者,比较康复新液漱口单用与康复新液漱口后绿袍散喷口腔黏膜的疗效与安全性,不良反应按常见不良事件评价标准4.0版评价。

主要发现

  • 3级黏膜炎在康复新液组为32.9%(23/70),在康复新液联合绿袍散组为11.4%(5/44),P=0.009。
  • 康复新液组疼痛评分为4.26±0.81,高于联合组的3.75±1.03,P=0.007。
  • 联合组症状缓解时间为3天,短于单药组的6天,P=0.000。
  • 康复新液组体重下降6.67±1.20 kg,大于联合组的5.95±0.94 kg,P=0.001。
  • 张口受限两组间无统计学差异,P=0.164。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and safety of Kangfuxin solution and lvpao powder on mucositis induced by radiation therapy in head and neck carcinoma patients. We retrospectively analyzed 114 patients with head and neck malignant tumors in our center. METHODS AND MATERIALS: Patients were given Kangfuxin solution to rinse the mouth or Lvpao powder sprayed on oral mucosa after the solution use. The side effect was evaluated by Common Terminology Criteria for Adverse Events version 4.0. RESULTS: The grade 3 mucositis occurred in 32.9% (23/70) and 11.4% (5/44) in Kangfuxin solution group and Kangfuxin solution + lvpao powder group, respectively (P = .009). The pain score of the Kangfuxin solution group was significantly higher than that of the Kangfuxin solution and lvpao powder group, with 4.26 ± 0.81 versus 3.75 ± 1.03 (P = .007). The time of symptom relief in the combined group was significantly shorter than that in the single drug group, with 3 days versus 6 days (P = .000). The weight loss of the former groups was bigger than that of the latter group (6.67 ± 1.20 kg vs 5.95 ± 0.94 kg; P = .001). There was no statistical difference in the limitations in mouth opening (P = .164). CONCLUSIONS: Lvpao powder is safe and effective as a mucosal repair drug in accelerating the recovery of patients and reducing their body weight.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen L, Lu F, Qian H, et al. Efficacy of Lvpao Powder on Radiation Therapy-Induced Mucositis: A Retrospective Study of 114 Patients With Head and Neck Carcinoma. Adv Radiat Oncol. 2023. PMID: 38778827. doi:10.1016/j.adro.2023.101434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。